HURA
NASD TuHURA Biosciences, Inc.$1.94 ↓ -0.04 (-2.02%) Trading Down from the previous close of $1.98, $0.11 below the day’s high of $2.05
- YTD change
- +156.38%
- vs 20-day SMA
- -6.62%
- vs 200-day SMA
- +4.81%
Price ranges
Price & Performance
+0.57 (+40.43%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 75.5% away from all-time highs of $7.93
- HURA is up 156% since the beginning of the year
- HURA is down 26% over the past 12 months
- HURA is down 7% over the past 1 month
- 14% of all HURA investors are betting against HURA
HURA reads poor: price sits above one of the two key moving averages, the 12-month move is -24.1%.
- Previous minute
- +$0.00
- Last hour
- +$0.02
- Last 5 days
- -7.62%
- vs 8-day SMA
- -6.62%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. Its lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. The company was founded by Michael Lawman, Patricia Lawman and James A. Bianco on May 4, 2023 and is headquartered in Tampa, FL.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.